INTRODUCTION:

Tonsillopharyngitis, commonly known as a sore throat, is a prevalent inflammatory condition affecting the tonsils and pharynx. While often considered a benign ailment, its impact on maternal and child health cannot be under estimated¹. In children, recurrent tonsillopharyngitis episodes can lead toimpaired academic performance, and compromised quality of life. Furthermore, complications such as tonsillar abscesses, obstructive sleep apnea, and systemic infections can necessitate hospitalizations and pose significant health risks².

For mothers, managing a child's recurrent tonsillopharyngitis episodes can result in increased caregiving responsibilities, emotional stress, and economic burdens. Given its widespread prevalence and implications for maternal and child health, optimizing tonsillopharyngitis management remains a critical healthcare priority^3,4

In recent years, the healthcare landscape has witnessed a paradigm shift towards personalized medicine, emphasizing individualized patient care based on unique genetic, environmental, and lifestyle factors. Personalized manag recognizes that healthcare interventions should be tailored to meet the specific needs and characteristics of each patient, rather than adopting a one-size-fits-all approach^5,6. In the context of tonsillopharyngitis, personalized management holds promise for improving treatment outcomes, minimizing adverse effects, and enhancing patient satisfaction. By considering individual patient factors such as age, immune status, comorbidities, and antibiotic resistance patterns, healthcare providers can develop targeted treatment strategies that optimize efficacy and minimize risks. Furthermore, personalized management may facilitate the early identification of high-risk individuals, allowing for proactive interventions and improved long-term health outcomes^7,8.

The rationale for embracing personalized management in tonsillitis within maternal and child health is multifaceted, rooted in scientific advancements, clinical observations, and ethical imperatives. Advances in microbiology, immunology, and molecular diagnostics have elucidated the complex etiological factors contributing to tonsillitis, highlighting the variability in disease mechanisms, pathogen profiles, and host responses among affected individuals. These insights underscore the limitations of a standardized approach and underscore the need for tailored interventions that account for individual variability in disease susceptibility, severity, and treatment response.

Furthermore, personalized management aligns with broader healthcare goals of promoting patient-centered care, enhancing health equity, and optimizing resource utilization within maternal and child health settings. By tailoring interventions to individual patient characteristics, healthcare providers can mitigate risks associated with recurrent infections, antibiotic overuse, and treatment-related complications, thereby reducing the burden on healthcare systems and improving cost-effectiveness⁹. Additionally, personalized management resonates with ethical principles of autonomy, respect for individual rights, and shared decision-making, empowering mothers and children to actively participate in treatment planning, informed consent processes, and health promotion activities related to tonsillitis management¹⁰.

The objective of this literature review is to evaluate the impact of personalized tonsillopharyngitis management on reducing recurrent infections and associated complications in children, examine the potential benefits of personalized approaches in enhancing maternal well-being, reducing caregiving burdens, and mitigating economic implications, assess the role of personalized management in addressing antibiotic resistance, optimizing healthcare resource utilization, and informing clinical practice guidelines., and Identify gaps in current research, highlight challenges in implementing personalized tonsillopharyngitis management, and propose recommendations for future investigations and healthcare policies.

RESEARCH FOCUS:

The primary research focus centers on exploring and evaluating the role of personalized management strategies for tonsillitis within the context of maternal and child health. This investigation seeks to understand how tailoring treatment approaches based on individual patient characteristics—such as age, immune status, recurrent infections, and antibiotic resistance patterns—can optimize outcomes, minimize complications, and enhance overall well-being^9,11,12.

RESEARCH PROBLEM:

The research problem centers on the deficiency of personalized management strategies for tonsillitis in maternal and child health. Current standardized treatment protocols often overlook individual variations, leading to suboptimal outcomes, complications, antibiotic misuse, and inefficiencies in healthcare delivery. Addressing this gap is crucial to enhance treatment effectiveness, minimize complications, and improve overall care quality for mothers and children affected by tonsillitis.

RESEARCH QUESTIONS:

1. How does personalized management impact the treatment outcomes of tonsillitis in maternal and child health compared to standardized approaches?

2. What are the individual patient characteristics (e.g., age, immune status, recurrent infections) that influence the effectiveness of personalized tonsillitis management strategies?

3. What are the potential benefits and limitations associated with implementing personalized management strategies for tonsillitis within maternal and child health contexts?

4. How do ethical considerations, such as autonomy and informed consent, shape the implementation and acceptance of personalized tonsillitis management approaches among mothers, children, and healthcare providers?

RESEARCH AIM:

The study aims to evaluate the effectiveness, safety, ethical implications, and broader impact of personalized management strategies for tonsillitis within maternal and child health sectors, with the goal of guiding clinical practices, shaping policy, and directing future research.

LITERATURE REVIEW:

Chronic Tonsillopharyngitis: Impact and Management during Pregnancy and Beyond:

Chronic tonsillopharyngitis is a persistent inflammation of the tonsils and pharynx, often characterized by recurrent sore throat, difficulty swallowing, and persistent discomfort. While it presents challenges in the general population, its management becomes particularly crucial during pregnancy due to potential complications for both the mother and child. This article aims to provide a comprehensive background on chronic tonsillopharyngitis, its implications during pregnancy, and strategies for management both during pregnancy and after childbirth¹².

Understanding Chronic Tonsillopharyngitis: Chronic tonsillopharyngitis typically arises from repeated bacterial or viral infections affecting the tonsils and surrounding tissues. Factors such as poor immune function, environmental irritants, and genetic predispositions contribute to its development. Symptoms include persistent sore throat, difficulty swallowing, swollen lymph nodes, and occasionally fever. Left untreated, it can lead to complications such as abscess formation, obstructive sleep apnea, and systemic infections.

Impact During Pregnancy:

During pregnancy, the physiological changes in the immune system and hormonal balance can exacerbate symptoms of chronic tonsillopharyngitis. Furthermore, the use of certain medications and antibiotics is restricted during pregnancy, limiting treatment options. The condition can lead to discomfort, sleep disturbances, and nutritional deficiencies, affecting the overall well-being of the mother and potentially influencing fetal development³.

Management Strategies:

Management of chronic tonsillopharyngitis during pregnancy requires a multidisciplinary approach involving obstetricians, otolaryngologists, and infectious disease specialists. Non-pharmacological interventions such as gargling with saline solutions, maintaining adequate hydration, and rest can provide symptomatic relief. However, in cases where medical intervention is necessary, careful consideration of the risks and benefits of medication use during pregnancy is essential¹⁶.

Postpartum Considerations:

For women with chronic tonsillopharyngitis, the condition may persist after childbirth. Breastfeeding mothers need to be cautious about transmitting infections to their infants, especially if the condition is exacerbated during the postpartum period. Close monitoring and follow-up care are essential to address any lingering symptoms and prevent complications²⁶.

Personalized management impacts the treatment outcomes of tonsillitis in maternal and child health compared to standardized approaches:

Personalized management of tonsillitis in maternal and child health involves tailoring treatment approaches to individual patient characteristics, considering factors such as age, immune status, and recurrent infections. This approach stands in contrast to standardized treatment protocols, which apply uniform strategies for a broad patient population. Examining the impact of personalized management on treatment outcomes compared to standardized approaches involves considering various aspects¹³ (Table 1).

Table 1 format provides a concise comparison between personalized and standardized approaches in managing tonsillitis within maternal and child health.

The individual patient characteristics (e.g., age, immune status, recurrent infections) that influence the effectiveness of personalized tonsillitis management strategies:

Several factors affect the personalized management of tonsillitis within maternal and child health contexts^19–21:

As we age our immune system is greatly affected, and the effectiveness of our immune systems deteriorates, leaving older persons more vulnerable to COVID-19, Streptococcus infection and other bacterial and viral infections. A study investigated the function of the immune system in terms of immune cells. They created three age-based groups young (less than 41 years old), middle-aged (between 41 and 64), and older (over 65).

They attempted to balance gender, BMI, frailty scores, and other health attributes to accomplish this goal. We evidenced that as they grew older, both sexes saw changes in the frequency and activity of distinct immune cell types. For example, there were decreases in the number of T cells—so named because they mature in the thymus gland—monocytes, which are formed in the bone marrow, and cytotoxic cells, which eliminate diseased, infected, or cancerous cells. Since T cells are in charge of recognising foreign pathogens and coordinating the body's adaptive immune response to establish a defence mechanism, their loss is especially significant²².

Immune status can also affect the way of body response to infection. Individuals with poor immunity due to HIV/AIDS, immunosuppressive medications, or other immunodeficiencies may present with tonsillitis differently, be more prone to infections, or react differently to treatment. On the other hand, Immunocompetent individuals may display conventional tonsillitis presentations and respond to routine treatments²³.

Frequent infection may increase the susceptibility to complications, antibiotic resistance, and treatment failures. Treatment effectiveness can be increased by customizing care strategies to address underlying causes of recurring infections (such as anatomical anomalies and patterns of microbial resistance).

Other comorbidities such as chronic respiratory diseases, cardiovascular diseases, or metabolic disorders may require personalized tonsillitis management strategies to address potential interactions, contraindications, or exacerbations related to their comorbidities. Besides, we should take into the consideration the patient preferences and lifestyle. Therefore, creation of individualised treatment programmes that encourage adherence, patient engagement, and positive outcomes can be facilitated by taking into account lifestyle concerns, cultural preferences, socioeconomic position, and other aspects ^24,25.

Potential limitations of personalized management strategies for tonsillitis within maternal and child health contexts:

Personalised medications come with a lot of difficulties, particularly when it comes to getting regulatory corporations to approve them for regular usage. Furthermore, there exist numerous concerns linked to the widespread use of personalised medications by various healthcare stakeholders, including physicians, executives in the field, insurance providers, and patients themselves. The majority of these obstacles centre on the necessity of demonstrating that personalised medicine tactics merely surpass standard medicine tactics. This is especially true given the prevalence of customised or personalised medicines²⁶. Besides, the personalized management strategies may require additional investigations to describe the precise treatment according to the described case, including specialized diagnostic tests, healthcare provider training, and time-intensive care planning, potentially posing challenges in resource-limited settings. Another limitation is the difficulty to customize the treatment according the multiple individual patient characteristics and factors may introduce complexity into clinical decision-making processes, requiring comprehensive assessments, interdisciplinary collaboration, and continuous monitoring^27–29.

Various obstacles are encountered in implementing personalized management strategies in maternal and child health. Strategies designed for individuals or communities might not seamlessly transfer to broader contexts, necessitating tailored adjustments, assessments, and implementation methods. Ethical considerations add complexity, requiring a balance between public health issues, individual care, and ethical principles such as justice and fairness. These aspects pose challenges in policy development and implementation. Additionally, the efficacy, uniformity, and consistency of tailored tonsillitis management plans could be affected by variations in clinical practices, patient preferences, healthcare provider expertise, and healthcare system elements^30,31.

MATERIALS AND METHODS:

General background:

Personalized management strategies for tonsillitis within maternal and child health contexts emphasize tailored approaches that consider individual characteristics such as age, immune status, recurrent infections, and antibiotic resistance patterns to optimize treatment outcomes³². This individualized care paradigm addresses the heterogeneity in disease presentation and response among mothers and children, promoting enhanced treatment efficacy, minimized complications, responsible antibiotic stewardship, and improved patient satisfaction. While offering significant benefits, including optimized care quality and patient-centeredness, personalized strategies also present challenges related to resource constraints, decision-making complexity, ethical considerations, and generalizability, necessitating continued research, interdisciplinary collaboration, and policy development to advance maternal and child health outcomes effectively^33,34.

Inclusion Criteria:

We incorporated various study designs, encompassing case series, randomized clinical trials, case-control studies, and systematic reviews, to provide a comprehensive understanding of the topic. Specifically, the focus was on studies that investigated personalized management strategies for tonsillitis especially within maternal and child health contexts. Additionally, most of the studies considered were recent, primarily spanning from 2018 to 2023, to ensure relevance and up-to-date insights.

Exclusion Criteria:

Conversely, we excluded studies and articles that lacked peer-reviewed validation, including proposals, procedures, letters, and opinions. Furthermore, research conducted before 2010 was deemed outdated and thus excluded from our review. Additionally, studies were disregarded if they did not align with the primary objectives of our investigation or if their focus diverged significantly from the designated topic of interest.

Information Sources:

For our research, we accessed several online databases, including Web of Science, Scopus, Google Scholar, PubMed, and the Cochrane Library, using targeted keywords such as "Personalized management," "Tonsillopharyngitis," "Maternal," and "Child" up to January 2024. This approach ensured a comprehensive and unbiased collection of relevant publications. The references cited in this paper were specifically selected due to their direct relevance to our research topic.

Data Collection:

Our data collection process comprised three distinct stages. Initially, we employed EndNote Software to systematically transfer the research findings from the electronic databases into a structured Microsoft Excel spreadsheet. Subsequently, during the second stage, we rigorously screened the titles and abstracts of the articles within this spreadsheet to ascertain their alignment with our research objectives. The third stage encompassed a meticulous examination of the full texts of the selected citations from the previous stage. Furthermore, to ensure a thorough review, we manually scrutinized the references of the included studies to identify any potentially overlooked research contributions.

Statistical Analysis:

Given the nature of our study as a narrative review, our analytical approach predominantly involved qualitative assessments of the selected studies. Although an initial attempt was made to perform a quantitative analysis, the heterogeneous nature of available data and the absence of comparable outcomes across studies precluded a quantitative synthesis. To provide robust evidence and contemporary insights, we focused on a qualitative analysis of pertinent studies, systematically presenting their findings and facilitating a comparative evaluation within the scope of our research topic.

RESULTS:

A systematic search employing a specific search strategy yielded 180 articles initially. Subsequent screening based on titles and abstracts narrowed down the selection to 100 articles for full-text evaluation. Upon thorough assessment, 45 articles were deemed relevant and subsequently utilized to inform and construct this review. Refer to Figure 1 for a graphical representation.

Figure 1. Comparative Utilization of Databases for Personalized Tonsillitis Management Research in Maternal and Child Health

We conducted our study based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations and guidelines (Figure 2) ³⁵.

Figure 2. PRISMA flow chart of the literature search.

Table 2 presents a summarized comparison of selected studies focusing on personalized and standardized medical interventions in the treatment of ear, nose, and throat (ENT) infections. This comparative analysis highlights the study designs, key findings, and inherent limitations, providing insight into the efficacy of personalized medicine in managing chronic ENT conditions.

DISCUSSION:

The discourse surrounding personalized management strategies for tonsillitis within the realm of maternal and child health is of paramount significance, considering its potential implications for treatment efficacy, patient satisfaction, and healthcare resource utilization. The present review endeavors to elucidate the multifaceted aspects of this approach, drawing parallels and distinctions with existing literature to provide a comprehensive understanding⁴⁰.

One salient finding from our analysis pertains to the efficacy of tailored interventions in optimizing treatment outcomes for mothers and children afflicted with tonsillitis. Our review corroborates findings from previous studies, underscoring the importance of individualized care approaches in addressing the heterogeneous nature of the disease presentation and response to treatment. For instance, Savoldi et al. (2023) highlighted the role of personalized management in enhancing treatment adherence and minimizing complications, aligning with our observations regarding improved patient satisfaction and reduced healthcare-associated burdens⁴¹. Jerzak et al. published the initial findings on tailored therapy for pregnant women after infection. They emphasized the benefits of individualized care strategies. Tailoring treatments to specific patient characteristics, such as age, immune status, and underlying health conditions, can lead to more targeted interventions and improved outcomes⁴², which supports our results.

Bissonnette et al.⁴³ used point-of-care molecular diagnostic technologies for personalized management of infectious diseases. They found that a personalized medicine approach allows patients to benefit significantly from enhanced management of infectious diseases. This method relies on clinically relevant genomic data from microbes obtained through specialized point-of-care (POC) devices and tests conducted close to patients or in nearby POC labs. The information is quickly communicated to the attending physician, reducing the time and potential errors associated with pre- and post-analytical stages of clinical microbiology testing, which in turn supports our findings. Another study by Haddad-Boubaker et al. focused on personalized management of infectious diseases. They reported that personalized or precision medicine is an evolving method aimed at enhancing patient care by administering the appropriate treatment at the optimal moment⁴⁴.

Contrastingly, while personalized strategies demonstrate promising outcomes, their implementation within maternal and child health contexts necessitates careful consideration of resource allocation, healthcare provider training, and interdisciplinary collaboration. Goetz and colleagues (2018) emphasized the challenges associated with integrating personalized care paradigms, citing logistical constraints, ethical considerations, and variability in healthcare provider expertise as potential barriers. Our findings resonate with these assertions, particularly concerning the resource-intensive nature, decision-making complexity, and ethical dilemmas intrinsic to personalized tonsillitis management ⁴⁵. Moving forward, the challenges ahead encompass enhancing both the efficiency of individual characterization and the development and evaluation of personalized medicines for their efficacy. While it's essential not to overlook broadly effective treatments, known as traditional 'blockbuster' drugs, identifying such interventions may become increasingly challenging in the future. Furthermore, the temporal dimension emerges as a pivotal factor influencing the relevance and applicability of personalized management strategies. A noteworthy observation from our review pertains to the predominance of recent studies (2018-2023), reflecting contemporary healthcare trends, technological advancements, and evolving patient preferences within maternal and child health settings ^46,47. This temporal focus contrasts with older studies predating 2010, which, while foundational, may lack alignment with current evidence-based practices, technological innovations, and patient-centered care paradigms.

Interestingly, our qualitative analysis underscores the predominance of narrative reviews and qualitative studies, reflecting the inherent complexities, heterogeneity, and multifactorial nature of personalized tonsillitis management. This observation resonates with existing literature, emphasizing the paucity of robust quantitative evidence and standardized outcome measures across studies, thereby precluding comprehensive meta-analytical synthesis and comparative evaluations. In juxtaposition with other studies, our review elucidates the nuanced interplay between personalized tonsillitis management strategies and broader healthcare imperatives, including antibiotic stewardship, patient-centered care, and healthcare equity. While existing literature acknowledges the potential benefits of personalized approaches, including optimized treatment efficacy and enhanced patient satisfaction, the complexities surrounding resource allocation, decision-making, ethics, and generalizability necessitate a multifaceted, context-specific approach. For instance, Stefanicka-Wojtas and colleagues (2023) emphasized the role of policy reforms, interdisciplinary collaboration, and patient engagement in facilitating the seamless integration of personalized care paradigms within maternal and child health contexts⁴⁸.

LIMITATIONS:

Our study faces limitations primarily due to the absence of randomized clinical therefore,considering the current shortage of randomized clinical trials, it is advisable to integrate a greater number of these trials into future research endeavors. Furthermore, as a narrative review predominantly encompassing observational studies, it presents findings descriptively rather than through pooled data analysis. Consequently, this approach limits objectivity and precludes comprehensive data synthesis. While narrative reviews offer an extensive overview of existing literature, facilitating a holistic understanding, they may not conclusively validate prevailing theories or adequately explore alternative hypotheses.

CONCLUSION:

In conclusion, while personalized management strategies for tonsillitis within maternal and child health contexts offer promising avenues for optimizing treatment outcomes, mitigating complications, and enhancing patient satisfaction, their implementation necessitates meticulous consideration of resource constraints, decision-making complexity, ethical considerations, and temporal relevance. By juxtaposing our findings with existing literature, this review underscores the imperative for ongoing research, interdisciplinary collaboration, policy development, and healthcare provider training to advance personalized tonsillitis management strategies, address existing challenges, and improve maternal and child health outcomes effectively.

CONFLICT OF INTEREST:

All authors declare no conflict of interest.

REFERENCES:

1. Gottlieb M, Long B, Koyfman A. Clinical Mimics: An Emergency Medicine-Focused Review of Streptococcal Pharyngitis Mimics. The Journal of emergency medicine [Internet]. 2018; May 1 [cited 2024; 54(5): 619–29. Available from: https://pubmed.ncbi.nlm.nih.gov/29523424/

2. Ali NS. Growth Hormone Receptor and Histopathological Study in Patients with Tonsillitis. Research Journal of Pharmacy and Technology [Internet]. 2018; Dec 31 [cited 2024; Jan 17]; 11(12): 5507–12. Available from: https://www.rjptonline.org/AbstractView.aspx?PID=2018-11-12-51

3. Ickrath P, Morbach H, Schwaneck EC, Gehrke T, Scherzad A, Hagen R, et al. [Recurrent infections of the upper aerodigestive tract in patients with primary immunodeficiency]. HNO [Internet]. 2019; 67(11): 819–24. Available from: https://pubmed.ncbi.nlm.nih.gov/31119330/

5. Anderson J, Paterek E. Tonsillitis. StatPearls [Internet]. 2023 Aug 8 [cited 2024 Jan 11]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK544342/

6. Rakhimov T, Mukhamediev M. Implementation of digital technologies in the medicine of the future. Futurity Medicine [Internet]. 2022; 1(2): 14–25. Available from: https://futurity-medicine.com/index.php/fm/article/view/7

7. Krasnova A. Vaccination of pregnant women against COVID-19 under martial law: a narrative review. Futurity Medicine [Internet]. 2022; 1(2): 4–13. Available from: https://futurity-medicine.com/index.php/fm/article/view/6

8. Bano AM, Karpagam K. Treatment and management of peritonsillar abscess -a review. Research Journal of Pharmacy and Technology. 2016;9(9):1541–4.

9. Ali NS. Growth Hormone Receptor and Histopathological Study in Patients with Tonsillitis. Research Journal of Pharmacy and Technology [Internet]. 2018; 11(12): 5507–12. Available from: https://rjptonline.org/AbstractView.aspx?PID=2018-11-12-51

10. Al Mozaini MA, Mansour MK. Personalized medicine: Is it time for infectious diseases? Saudi Medical Journal [Internet]. 2016; 37(12): 1309. Available from: /pmc/articles/PMC5303767/

11. Al-Abedine HZ, Zrieki A. The High Necessity of Rapid Antigen Detection Test (RADT) use to Guide Antibiotic Prescribing Pattern for Acute Pharyngotonsillitis in Syria. Research Journal of Pharmacy and Technology [Internet];14(6):2962–70. Available from: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-6-9

12. Mateescu MC, Grigorescu S, Socea B, Bloanca V, Grigorescu OD. Contribution to the Personalized Management of the Nosocomial Infections: A New Paradigm Regarding the Influence of the Community Microbial Environment on the Incidence of the Healthcare-Associated Infections (HAI) in Emergency Hospital Surgical Departments. Journal of Personalized Medicine [Internet]. 2023;13(2):210. Available from: /pmc/articles/PMC9968232/

13. Liu WY, Chien CW, Tung TH. Healthcare practice strategies for integrating personalized medicine: Management of COVID-19. World Journal of Clinical Cases [Internet]. 2021;9(29):8647. Available from: /pmc/articles/PMC8546804/

14. Moser C, Lerche CJ, Thomsen K, Hartvig T, Schierbeck J, Jensen PØ, et al. Antibiotic therapy as personalized medicine – general considerations and complicating factors. APMIS [Internet]. 2019; 127(5): 361–71. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/apm.12951

15. Swapnaa B, Santhosh Kumar V. Personalized Medicine - A Novel approach in Cancer Therapy. Research Journal of Pharmacy and Technology [Internet]. 2017;10(1):341–5. Available from: https://www.rjptonline.org/AbstractView.aspx?PID=2017-10-1-69

16. Leigh A, Simmons CD, Drake TW, Gaudet ;, Snyderman R. Personalized Health Planning in Primary Care Settings. Federal Practitioner [Internet]. 2016;33(1):27. Available from: /pmc/articles/PMC6366608/

17. Savoldi A, Mutters NT, Tacconelli E. Personalized infection prevention and control: a concept whose time has arrived. Antimicrobial Stewardship and Healthcare Epidemiology. 2023; 3(1).

18. Murali M, Kothandan S, Chandrasekaran M, Singh SK, Kuppusamy G, Radhakrishnan A. Fluticasone and Cyclophosphamide towards the track of personalized Medicine. Research Journal of Pharmacy and Technology [Internet]. 2021; 14(1): 179–84. Available from: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-1-31

19. Ramayanam NR, Amarnath RN, Vijayakumar TM. Pharmacogenetic Biomarkers and Personalized Medicine: Upcoming Concept in Pharmacotherapy. Research Journal of Pharmacy and Technology [Internet]. 2022; 15(9): 4289–92. Available from: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-9-80

20. Alimukhamedov U. Acute renal failure in newborns in the practice of a pediatrician of the future. Futurity Medicine [Internet]. 2022; 1(4): 19–29. Available from: https://futurity-medicine.com/index.php/fm/article/view/17

21. Sukhostavets N. Psycho-rehabilitation adaptation of pregnant women and mothers in the postpartum period who experienced traumatic events during the war. Futurity Medicine [Internet]. 2022;1(3):4–12. Available from: https://futurity-medicine.com/index.php/fm/article/view/11

22. Stevenson DK, Wong RJ, Aghaeepour N, Maric I, Angst MS, Contrepois K, et al. Towards personalized medicine in maternal and child health: integrating biologic and social determinants. Pediatric research [Internet]. 2021 Jan 1 [cited 2024 Jan 12];89(2):252. s/PMC8061757/

23. McAlister FA, Laupacis A, Armstrong PW. Finding the right balance between precision medicine and personalized care. CMAJ : Canadian Medical Association Journal [Internet]. 2017;; 189(33): E1065. Available from: /pmc/articles/PMC5566606/

24. Kwame A, Petrucka PM. A literature-based study of patient-centered care and communication in nurse-patient interactions: barriers, facilitators, and the way forward. BMC Nursing [Internet]. 2021; 20(1): 1–10. Available from: https://bmcnurs.biomedcentral.com/articles/10.1186/s12912-021-00684-2

25. Márquez EJ, Chung C han, Marches R, Rossi RJ, Nehar-Belaid D, Eroglu A, et al. Sexual-dimorphism in human immune system aging. Nature Communications 2020 ;11(1):1–17. Available from: https://www.nature.com/articles/s41467-020-14396-9

26. Issenova S, Bodykov G, Bishekova B, Kabul B, Saparaliyeva A, Kazybayeva A. Uncomplicated Pregnancy and Birth of a Healthy Mature Newborn with a Giant Tumor of Both Frontal Lobes of the Brain with Dislocation: Medical History. Electronic Journal of General Medicine [Internet]. 2021; 18(6): em336. Available from: https://doi.org/10.29333/ejgm/11337

27. Goetz LH, Schork NJ. Personalized Medicine: Motivation, Challenges and Progress. Fertility and sterility [Internet]. 2018; 109(6): 952. Available from: /pmc/articles/PMC6366451/

28. Jaskulski S, Nuszbaum C, Michels KB. Components, prospects and challenges of personalized prevention. Frontiers in Public Health [Internet]. 2023; 11. Available from: /pmc/articles/PMC9978387/

29. Brothers KB, Rothstein MA. Ethical, legal and social implications of incorporating personalized medicine into healthcare. Personalized medicine [Internet]. 2015;12(1):43. Available from: /pmc/articles/PMC4296905/

30. Weyant C, Brandeau ML. Personalization of Medical Treatment Decisions: Simplifying Complex Models while Maintaining Patient Health Outcomes. Medical decision making : an international journal of the Society for Medical Decision Making [Internet]. 2022; 42(4): 450. Available from: /pmc/articles/PMC8858337/

31. Rubin DB, van der Laan MJ. Statistical Issues and Limitations in Personalized Medicine Research with Clinical Trials. The international journal of biostatistics [Internet]. 2012; 8(1):18. Available from: /pmc/articles/PMC6038934/

32. Shegai P V., Shatalov PA, Zabolotneva AA, Falaleeva NA, Ivanov SA, Kaprin AD. Challenges Faced by Clinicians in the Personalized Treatment Planning: A Literature Review and the First Results of the Russian National Cancer Program. Critical Care Research and Practice [Internet]. 2021; 2021. Available from: /pmc/articles/PMC8483928/

33. Meghana ISS, Bhat AR, Bhandary R. Metabolomics: a step towards personalized periodontal diagnosis. Research Journal of Pharmacy and Technology [Internet]. 2023; 16(11): 5439–43. Available from: https://www.rjptonline.org/AbstractView.aspx?PID=2023-16-11-75

34. Radhakrishnan A, Kuppusamy G, Venkatachalam S, Vijayakumar R, Shanmukhan NK. Personalized Nano Delivery Strategy in Treating Uveitis. Research Journal of Pharmacy and Technology [Internet]. 2019; 12(4): 1997–2008. Available from: https://www.rjptonline.org/AbstractView.aspx?PID=2019-12-4-89

35. Kamala Kumari P V., Srinivasa Rao Y. Personalized Medicine- A Review. Research Journal of Pharmacy and Technology [Internet]. 2019; 12(8): 3989–92. Available from: https://www.rjptonline.org/AbstractView.aspx?PID=2019-12-8-77

36. Moher D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Chinese edition). Journal of Chinese Integrative Medicine. 2009; 7(9):889–96.

37. Ickrath P, Morbach H, Schwaneck EC, Gehrke T, Scherzad A, Hagen R, et al. [Recurrent infections of the upper aerodigestive tract in patients with primary immunodeficiency]. HNO [Internet]. 2019; 67(11): 819–24. Available from: https://pubmed.ncbi.nlm.nih.gov/31119330/

38. Koskenkorva T, Koivunen P, Läärä E, Alho OP. Predictive factors for quality of life after tonsillectomy among adults with recurrent pharyngitis: a prospective cohort study. Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery [Internet]. 2014; 39(4): 216–23. Available from: https://pubmed.ncbi.nlm.nih.gov/24863677/

39. Bergquist SH, Lobelo F. The Limits and Potential Future Applications of Personalized Medicine to Prevent Complex Chronic Disease. Public Health Reports [Internet]. 2018; 133(5): 519. Available from: /pmc/articles/PMC6134562/

40. Kaier K, Metzner G, Horstmeier L, Bitzer EM, Heimbach B, Kiekert J, et al. The economic impact of a local, collaborative, stepped, and personalized care management for older people with chronic diseases: results from the randomized comparative effectiveness LoChro-trial. BMC Health Services Research [Internet]. 2023; 23(1): 1422. Available from: /pmc/articles/PMC10724907/

41. Handy L, Cadilla A, Werk L, Diaz MC, Franciosi J, Dent J, et al. Impact of Personalized Audit and Feedback on Management of Pediatric Outpatient Community-Acquired Pneumonia. Open Forum Infectious Diseases [Internet]. 2017: S501. Available from: /pmc/articles/PMC5631442/?report=abstract

42. Savoldi A, Mutters NT, Tacconelli E. Personalized infection prevention and control: a concept whose time has arrived. Antimicrobial Stewardship & Healthcare Epidemiology : ASHE [Internet]. 2023; 3(1). Available from: /pmc/articles/PMC10523548/

43. Jerzak M, Szafarowska M. Preliminary Results for Personalized Therapy in Pregnant Women with Polycystic Ovary Syndrome During the COVID-19 Pandemic. ArchivumImmunologiae et TherapiaeExperimentalis [Internet]. 2022; 70(1): 13. Available from: /pmc/articles/PMC8943102/

44. Bissonnette L, Bergeron MG. Infectious Disease Management through Point-of-Care Personalized Medicine Molecular Diagnostic Technologies. Journal of Personalized Medicine [Internet]. 2012; 2(2): 50. Available from: /pmc/articles/PMC4251365/

45. Haddad-Boubaker S, Mbarek H, Yassine HM. Editorial: Personalized medicine and infectious disease management. Frontiers in Medicine [Internet]. 2023; 10. Available from: /pmc/articles/PMC10216473/

46. Goetz LH, Schork NJ. Personalized Medicine: Motivation, Challenges and Progress. Fertility and sterility [Internet]. 2018; 109(6): 952. Available from: /pmc/articles/PMC6366451/

47. Bergquist SH, Lobelo F. The Limits and Potential Future Applications of Personalized Medicine to Prevent Complex Chronic Disease. Public Health Reports [Internet]. 2018; 133(5): 519. Available from: /pmc/articles/PMC6134562/

48. Yamamoto Y, Kanayama N, Nakayama Y, Matsushima N. Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease. Journal of Personalized Medicine [Internet]. 2022; 12(3). Available from: /pmc/articles/PMC8949099/

49. Stefanicka-Wojtas D, Kurpas D. Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions). Journal of Personalized Medicine [Internet]. 2023; 13(3). Available from: /pmc/articles/PMC10058568/

Received on 19.03.2024 Modified on 22.05.2024

Research J. Pharm. and Tech 2024; 17(9):4519-4527.

DOI: 10.52711/0974-360X.2024.00699

Aspect	Personalized Approach	Standardized Approach
Treatment Efficacy¹⁴.	Tailors treatments to individual characteristics for targeted therapy.	Applies uniform strategies, potentially leading to suboptimal outcomes for specific patient groups.
Reduction in Complications¹⁵.	Addresses individual risk factors, contributing to fewer complications like abscess formation.	This may increase the likelihood of complications due to a lack of consideration for individual variations.
Antibiotic Stewardship¹⁶	Facilitates judicious antibiotic use by considering individual needs, reducing the risk of antibiotic resistance.	Overuse/misuse of antibiotics may contribute to the development of antibiotic-resistant strains.
Patient Satisfaction & Adherence¹⁷.	Enhances patient satisfaction and adherence by considering individual preferences.	This may result in dissatisfaction and non-compliance due to a lack of consideration for individual patient factors.
Cost-Effectiveness¹⁸.	Initial higher costs may lead to long-term savings by reducing complications and antibiotic resistance.	Lower upfront costs may be offset by increased expenses related to complications and antibiotic resistance over time.

STUDY	STUDY DESIGN	RESULTS AND SUMMARY	LIMITATION
Ickrath et al ³⁶	retrospective case series	The research involved 85 participants, with 66% experiencing acute exacerbations of chronic rhinosinusitis, cervical lymphadenitis, acute tonsillitis, or acute otitis media. However, due to the retrospective nature of the study, detailed information on infection frequencies and dates was unavailable. The study concludes that individuals with primary immunodeficiency exhibit a higher prevalence of ear, nose, and throat (ENT) infections compared to the general population. This underscores the importance for ENT specialists to consider primary immunodeficiency in their diagnostic process and utilize targeted diagnostic methods when needed.	Case series studies, while informative, come with inherent limitations that impact their ability to establish causal relationships and generalize findings. One primary constraint is the absence of a comparison group, hindering the determination of intervention effectiveness or causal links.
Koskenkorva et al ³⁷	Prospective cohort design.	No matter what caused the episodes, adult patients with recurrent pharyngitis were generally delighted with their tonsillectomy. The patients who benefited most from the operation were predicted by clinical characteristics in a very moderate way.	They included 142 patients which is notable constraint is the relatively limited sample size, especially in analyses utilizing preoperative symptom diary data as predictors. Consequently, the estimation results exhibited wider error margins due to the smaller dataset.
Bergquist et al ³⁸	Review article	The transformative possibilities brought about by genomic science are poised to reshape the landscape of medicine in the future. Yet, chronic diseases stem from intricate, interconnected pathways and environmental factors, posing a fundamental constraint on the effectiveness of a gene-centric approach to personalized prevention. To fully harness the potential of genomic medicine in preventing chronic diseases, interventions must extend beyond genes and consider environmental interactions.	inherent limitation of the review such as the potential for publication bias exists, as studies with positive or significant results are more likely to be published, potentially skewing the overall interpretation.
Žiemytė et al ³⁸	double-blind, randomized clinical trial	The utilization of the impedance system is endorsed for enhanced personalized antibiotic selection, as indicated by the outcomes of clinical and microbiological parameters, coupled with its cost-effectiveness and swift analysis.	Heterogeneity in antibiotic susceptibility among strains from the same species
Kaier et al ³⁹	parallel randomized controlled trial	The investigation found no cost distinctions among older individuals receiving LoChro-Care compared to those receiving standard care. To establish more reliable evidence on the cost implications of LoChro-Care, additional studies with larger sample sizes should be conducted before implementing the intervention	cost-effectiveness analysis